AI & Automation Solutions

LLY, ABBV stocks hit all-time high - here's what's driving investor enthusiasm today. Published: Oct 31 2026, 01:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us LLY shares extended gains on bullish Wall Street action after the company raised its full-year 2026 outlook. * UBS said Lilly's underlying momentum and a higher Q4 growth run rate could potentially make current estimates appear too conservative. * AbbVie's Q3 revenue rose 10.3% to $17.40 billion, driven by over 16% growth in its immunology business. * AbbVie raised its FY 2026 revenue forecast to $67.8 billion from $67.6 billion and adjusted EPS guidance to $13.95 - $13.99 from $13.76 - $13.96. Shares of Eli Lilly (LLY) and AbbVie (ABBV) climbed to new record highs on Friday after the pharmaceutical behemoths reported stronger-than-expected third-quarter earnings and raised their full-year 2026 outlooks. LLY stock was up 3.5% at the time of writing, extending its gains to a fifth straight session. It is on track to post its biggest monthly gains since November 2025. Meanwhile, ABBV shares rose 1.6%. Wall Street sees upside for LLY after Q3 earnings beat. Analysts turned bullish on Eli Lilly (LLY) on Friday, betting on its obesity-drug leadership and expanding pipeline. Scotiabank raised its target to $1,605 from $1,300 and held an 'Outperform' rating, expecting Lilly to maintain its obesity-market dominance through 'next-generation products' and acquisitions. Truist lifted its target to $1,612 from $1,376, and maintained a 'Buy' rating. The firm said Lilly currently has only about 10% market penetration in obesity, and expansion of its incretin franchise and pipeline will cement its dominance in "diabesity" for years to come. On Thursday, Lilly reported a 39% increase in Q3 revenue to $24.4 billion, while adjusted earnings rose 7% to $7.48 per share. Mounjaro sales surged 65% to $10.72 billion, while Zepbound revenue rose 49% to $5.35 billion. Lilly also raised its 2026 revenue outlook to $91 billion-$92 billion from $85 billion-$87 billion. However, the company trimmed its bottom-line guidance to $35-$36 per share from $35.5-$36.5 per share. UBS said Lilly's underlying momentum and a higher Q4 growth run rate could potentially make current estimates appear too conservative. Retail sentiment surrounding LLY on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier. The stock has gained more than 31% so far in 2026. AbbVie raises FY26 outlook. AbbVie reported better-than-expected Q3 earnings on Friday, driven by strong growth in its immunology business. Revenue rose 10.3% to $17.40 billion, beating Wall Street's estimates of $17.34 billion, according to Fiscal.ai. Adjusted earnings more than doubled to $3.82 per share, exceeding consensus estimates of $3.77 per share. Immunology revenue increased 16.3%, with Skyrizi, its autoimmune drug for psoriatic arthritis and Crohn's disease, among others, generating $5.78 billion. Rinvoq, prescribed for inflammatory conditions including rheumatoid arthritis and eczema, saw sales surge nearly 24%. AbbVie also raised its FY 2026 revenue forecast to $67.8 billion from $67.6 billion and adjusted EPS guidance to $13.95 - $13.99 from $13.76 - $13.96. In a call with analysts, chief scientific officer Roopal Thakkar said the company is interested in expanding its obesity-treatment pipeline, according to The Fly. Meanwhile, retail sentiment for ABBV on Stocktwits remained 'neutral' over the past 24 hours. The stock has gained about 29% in 2026. For updates and corrections, email newsroom[at]stocktwits[dot]com< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

Eli Lilly's third-quarter revenue rose 39% year on year, driven by its obesity and diabetes drugs, and the company raised its 2026 revenue outlook for the fourth time this year. Tirzepatide brands Mounjaro and Zepbound brought in $10.7 billion and $5.4 billion respectively, about $16.1 billion in total. That is more than the total quarterly revenue of Novartis, GSK, and Bristol Myers Squibb. Mounjaro sales grew 65% and Zepbound 59%. Growth slowed from 48% in the second quarter, largely because of pricing pressure. Lilly now expects 2026 revenue of $91 billion to $92 billion, up from $85 billion to $87 billion. Citi analysts called it "another exceptional quarter" and named Lilly their favourite large biopharma company.

Eli Lilly stock jumps: company raises revenue target again. October 29, 2026, 6:02 p.m. The pharmaceutical company Lilly can continue to rely on the weight-loss drug Zepbound and the diabetes drug Mounjaro. Both blockbusters drove growth in the third quarter as well, with billions in revenue. As a result, the US manufacturer performed better than expected in the quarter. In view of persistently high demand, CEO David Ricks once again significantly raised the company's revenue forecast for the year. In early US trading, the stock rose 8 percent to a record level. For 2026, the company now expects revenue to rise to 91 to 92 billion US dollars (around 81.7 to 82.6 billion euros), after just over 65 billion in 2025, Lilly announced in Indianapolis. At the previous forecast increase in August, CEO Ricks had still projected revenue of 85 to 87 billion dollars for this year. By contrast, the company slightly lowered its annual target for adjusted earnings per share (EPS) by half a dollar at both ends: it now expects an increase to 35 to 36 dollars per share. The reason for the slight cut was said to be charges for acquired development and research projects. In the third quarter, Lilly increased revenue by 39 percent to 24.4 billion dollars. Analysts had expected 22.5 billion on average. The diabetes drug Mounjaro brought in 10.7 billion dollars, while the weight-loss treatment Zepbound brought in 5.3 billion. Both medications exceeded market expectations. The still relatively new weight-loss pill Foundayo, however, fell short of expectations. It generated 184 million dollars in the quarter, while analysts had expected almost 50 million dollars more. The once-daily medication competes with the weight-loss pill Wegovy from Danish rival Novo Nordisk. Net profit rose by just over 15 percent in the quarter to around 6.5 billion dollars. The increase in adjusted earnings per share was smaller by comparison at seven percent to 7.48 dollars, as high research costs weighed. However, analysts had even expected a decline here. The booming business with obesity drugs has made Lilly the world's most valuable pharmaceutical company and given the company financial flexibility for increasingly ambitious expansion. To secure growth in the long term, the company - like competitor Novo Nordisk - is working on additional weight-loss agents, among other things. This includes a new generation of treatments that are more effective or have fewer side effects. One focus is the experimental agent retatrutide, which is still being clinically tested and could offer greater weight loss than previous treatments. In addition, Lilly is currently opening up new areas such as women's health and psychedelic substances. At the same time, competition and price pressure in the weight-loss drug market are intensifying, partly because Novo Nordisk is trying to win back lost market share. Eli Lilly stock was temporarily up 6.38 percent at 1,370.55 US dollars in NYSE trading. /tav/nas/jha/ Indianapolis (dpa-AFX) Selected leveraged products on Eli Lilly. With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on Eli Lilly. | Name | leverage | knock-out | issuer | | Turbo long on Eli Lilly | 4.99 | 1,094.61 | Morgan Stanley | | Turbo long on Eli Lilly | 4.96 | 1,089.44 | Morgan Stanley | | Turbo long on Eli Lilly | 4.94 | 1,086.49 | Morgan Stanley | | Turbo long on Eli Lilly | 4.94 | 1,086.72 | Morgan Stanley | | Mini future long on Eli Lilly | 4.84 | 1,134.19 | Morgan Stanley | You can obtain the base prospectus as well as the final terms and the key information documents here: MR199K, MR199J, MR0JMR, MR0FUN, MR81FX. Please also note the further information** on this advertisement. Risk note: On average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.